Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
Super investors like Buffett and Michael Bury piled heavily into UnitedHealthcare in Q2, signalling confidence that the sector's business model remains intact despite recent headwinds. CVS has emerged as a top performer in 2025, with strong revenue growth and raised guidance, outpacing struggling peers like UnitedHealth. The sector faces ongoing uncertainties—rising costs, regulatory scrutiny, and budget cuts—but long-term healthcare spending trends remain favorable.
CVS Health commits $20B to build an open health platform, joining tech giants in a push to streamline patient care access nationwide.
CVS appears well-poised on strong Q2 revenue growth, raised full-year guidance and momentum in key healthcare segments.
STNE, CVS, KT, KB and USNA stand out in August for low P/B ratios and strong growth forecasts, making them value stock contenders.
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CVS Health boosts 2025 EPS guidance again as Health Care Benefits and PBM businesses drive growth.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
These top medical stocks may be able to provide defensive safety after President Trump's tariff hikes and July's unfavorable jobs report led to a market selloff.
CVS is focusing heavily on technology-led care after posting solid Q2 earnings. “We are building momentum as we navigate what continues to be a dynamic and evolving environment,” Chief Executive David Joyner told analysts on an earnings call Thursday (July 31), crediting the company's “diversified business” for offsetting swings in medical costs.
CVS Health beats on Q2 earnings and raises 2025 EPS outlook, lifting shares nearly 8% on strong segment growth and margin gains.
Although the revenue and EPS for CVS Health (CVS) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.